10-Year Heart Attack & Stroke Risk — ACC/AHA Pooled Cohort Equations (2013)
Check any present — these can shift the statin decision, especially in borderline or intermediate-risk patients.
Presence of risk enhancers supports initiating or intensifying statin therapy, particularly when 10-year risk is borderline (5–7.4%) or intermediate (7.5–19.9%).
If statin treatment remains uncertain after reviewing risk and enhancers, a CAC scan is the ACC/AHA-recommended tie-breaker. CAC = 0 substantially lowers near-term risk and supports deferring statin (absent other risk enhancers). CAC ≥ 100 or ≥75th percentile for age/sex supports initiating statin. Use the Calcium Score Calculator →
Per the 2018 ACC/AHA Cholesterol Management Guideline, statin therapy decisions for primary prevention are structured around four risk strata:
| Risk Category | 10-Year Risk | Statin Recommendation |
|---|---|---|
| 🟢 Low | < 5% | Lifestyle counseling. Statin generally not indicated unless LDL ≥ 190 mg/dL. |
| 🔵 Borderline | 5–7.4% | Discuss risk-enhancing factors. Consider moderate-intensity statin if enhancers present. Consider CAC if uncertain. |
| 🟠 Intermediate | 7.5–19.9% | Moderate-to-high intensity statin recommended. Consider CAC if uncertain. Optimize lifestyle risk factors. |
| 🔴 High | ≥ 20% | High-intensity statin recommended. Consider cardiology referral. Assess for secondary lipid causes. |
The Pooled Cohort Equations (PCE) were developed by the ACC/AHA Risk Assessment Work Group and published in 2013 (Goff DC Jr et al., Circulation 2014;129:S49–S73). They estimate the 10-year risk of a first hard ASCVD event — defined as nonfatal myocardial infarction, coronary heart disease death, or fatal/nonfatal stroke. The equations were derived from pooled data from five major US epidemiological cohort studies: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Coronary Artery Risk Development in Young Adults (CARDIA) study, and the Framingham Original and Offspring cohorts.
Four separate equations were derived — one each for White males, White females, African American males, and African American females — reflecting meaningful differences in the absolute risk contribution of each risk factor across populations. Each equation applies log-transformed continuous variables (age, total cholesterol, HDL cholesterol, systolic BP) to a Cox proportional hazards model structure, yielding a 10-year survival probability that is converted to absolute risk.
Enter age (40–79), biological sex, and race. Enter total cholesterol, HDL cholesterol, and systolic BP in the units shown. For other racial/ethnic groups, the White equation is used per guideline recommendation — this should be noted in clinical documentation. Check the clinical factors that apply. Hit "Calculate" to see the 10-year ASCVD risk estimate.
Interpret the result in clinical context alongside the patient's risk-enhancing factors. When the treatment decision remains uncertain, coronary artery calcium (CAC) scoring is the preferred reclassification tool.
Risk overestimation: Multiple studies have demonstrated that the PCE substantially overestimates 10-year ASCVD risk in contemporary populations — by 75–150% in some cohorts — due to improved prevention since the 1990s derivation studies. Clinicians should interpret results conservatively near decision thresholds.
Race and ethnicity: Race-specific equations exist only for White and African American individuals. For Hispanic, East Asian, South Asian, Native American, and multiracial patients, the White equation is used as an approximation — with known underestimation for South Asians and possible overestimation for some East Asians. This limitation should be documented.
Variables not captured: LDL-C, Lp(a), hs-CRP, CAC score, ABI, kidney function, and inflammatory conditions are not in the equation — these are addressed through the risk-enhancers framework.
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 Suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.98
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.003